Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in TEM.
← Back to Free Index

TEM

Analysis as of: 2026-04-28
Tempus AI, Inc.
Tempus combines molecular testing, clinician workflow software, and governed clinical data products to support precision medicine for providers and drug developers.
ai biotech enterprise healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Data rights plus workflow, if margins catch up
The core bull case is a shift from selling tests toward owning more of the oncology decision workflow and research evidence stack. That can support strong value creation, but only if revenue mix and operating leverage improve fast enough to justify a platform valuation.

Analysis

Thesis
Tempus can grow from a fast-growing precision-medicine company into a higher-value oncology operating layer if it keeps converting testing volume and governed data rights into larger workflow, evidence, and research contracts faster than regulation and capital needs compress its multiple.
Last Economy Alignment
Tempus benefits as cheap AI increases the value of hard-to-copy clinical data, trusted healthcare workflows, and verified decision support; the main cap is regulation, not model scarcity.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.8x (from 5 most recent analyses)
Reasoning
The upside is driven more by mix shift and contract scope than by heroic multiple expansion. Tempus already has the raw pieces: testing flow, provider embed, pharma relationships, and governed data. If those pieces get wrapped into larger recurring care and evidence contracts, revenue can compound well above market norms while the valuation remains disciplined for a regulated healthcare business.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is not product novelty; it is whether Tempus can turn good assets into self-funding economics. If reimbursement, data monetization, or enterprise workflow conversion disappoint, the company can still grow while the market values it more like a diagnostics business than a higher-multiple healthcare platform.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.68
They control hard-to-recreate clinical and molecular data and sit inside doctor workflows, so each new test and customer can make the system smarter and stickier. The risk is that privacy rules, reimbursement limits, or weak proof of savings leave them looking more like a good lab business than a true healthcare operating layer.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$72.83
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case